Efficacy News and Research

RSS

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

1 Dec 2015

Advances in leadless pacing: an interview with Dr. Reddy

Pacemakers have been around for a very long time, they're great devices, critical for many people who have slow heartbeats. While they're very effective, they have some issues. There are two main aspects relating to these issues.

1 Dec 2015

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

With global health services increasingly worried about the rise of antibiotic resistant diseases, researchers at Maynooth University have discovered a compound whose anti-MRSA qualities pave the way for the development of a new class of antibiotics.

1 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Study analyzes effect of music therapy on palliative care patients

Music therapy can enhance terminally ill patients' wellbeing and relaxation. This treatment has been known since the 1970s, but there is little scientific research on the subject. A recent randomized controlled trial by Marco Warth et al. in Deutsches Ärzteblatt International (Dtsch Arztebl Int 2015; 112: 788-94) analyzes the effect of music therapy on palliative care patients.

30 Nov 2015

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Research paves way for clinical trials of cell therapies to treat Parkinson's disease, spinal cord injury

Stem cells that have been specifically developed for use as clinical therapies are fit for use in patients, an independent study of their genetic make-up suggests.

26 Nov 2015

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

In the five decades since camptothecin was first isolated from the bark of a tree used in traditional Chinese medicine and identified as a powerful anticancer agent, several thousand chemicals with similar structures and functions have been investigated. And while two of these analog compounds, irinotecan and topotecan, have been approved in the U.S. as treatments for cancer, both are associated with significant shortcomings.

26 Nov 2015

Study sheds new light on the controversy surrounding common osteoarthritis treatment

Injections of hyaluronic acid (HA) are a common treatment of pain in osteoarthritis of the knee - a condition that affects 27 million Americans according to the Centers for Disease Control and Prevention. The injections replace natural HA that has depleted from one's joints, which can cause pain and stiffness due to the lack of lubrication between bones moving against each other.

26 Nov 2015

New drug combination shows promise in treating men with metastatic prostate cancer

A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.

26 Nov 2015

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).

25 Nov 2015

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement") with two Asia-based venture capital firms (the "New Investors"), pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary via a private placement.

25 Nov 2015

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

25 Nov 2015

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

25 Nov 2015

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

24 Nov 2015

BioThrax approved to prevent disease after exposure to anthrax spores

The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine's new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure.

24 Nov 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Notre Dame researchers discover compound that speeds up diabetic wound healing

Non-healing chronic wounds are a major complication of diabetes, which result in more than 70,000 lower-limb amputations in the United States alone each year. The reasons why diabetic wounds are resistant to healing are not fully understood, and there are limited therapeutic agents that could accelerate or facilitate their repair.

23 Nov 2015

Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

A new study reveals that the liver's cannabinoid receptors could be targeted to fight liver cancer in some patients; and it offers a way to predict what treatments have the best chance of working.

23 Nov 2015

Researchers receive $6 million to further develop potential treatment for cocaine abuse

University of Kentucky College of Pharmacy Professor Chang-Guo Zhan, along with fellow UK Professors Fang Zheng and Sharon Walsh, and Professor Mei-Chuan Ko from Wake Forest University, recently received $6 million in funding over five years to further develop a potential treatment for cocaine abuse.

21 Nov 2015

Efficacy News and Research

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Advances in leadless pacing: an interview with Dr. Reddy

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Study analyzes effect of music therapy on palliative care patients

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Research paves way for clinical trials of cell therapies to treat Parkinson's disease, spinal cord injury

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

Study sheds new light on the controversy surrounding common osteoarthritis treatment

New drug combination shows promise in treating men with metastatic prostate cancer

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

BioLight signs joint financing agreement with two Asia-based venture capital firms

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

BioThrax approved to prevent disease after exposure to anthrax spores

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Notre Dame researchers discover compound that speeds up diabetic wound healing

Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

Researchers receive $6 million to further develop potential treatment for cocaine abuse

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News